Biotech · Private company
Velicept Therapeutics, Inc.
Track this companyFree. Adds Velicept Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Solabegron immediate release tablets, high dosePhase 2 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
- Solabegron immediate release tablets, low dosePhase 2 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
- Solabegron modified release tablets, high dosePhase 2 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
- Solabegron modified release tablets, low dosePhase 2 · Overactive BladderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)PHASE2 · COMPLETED · started Jul 9, 2018ClinicalTrials.gov NCT03594058 · fetched Nov 12, 2026
- Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult WomenPHASE2 · COMPLETED · started Feb 19, 2018ClinicalTrials.gov NCT03475706 · fetched Nov 12, 2026